What type of study is this?

This is a Systematic Review study (also classified as: Phase 2, Phase 3).

October 9, 2025Open Access

Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic Advances

View Full Paper

Ask AI

Bookmark

Authors

This systematic review evaluates immunotherapy outcomes in bladder cancer, suggesting intravesical strategies outperform systemic therapies.

Intravesical therapies exhibited superior efficacy in bladder cancer treatment, highlighting their promise in clinical management.
Nadofaragene Firadenovec achieved a remarkable complete response rate of 75.2% with durability exceeding 12 months.
Phase 2 and 3 clinical trials were used to synthesize findings, demonstrating a preference for intravesical immunotherapy approaches.
Intravesical strategies exhibit better safety profiles compared to systemic treatments, reducing severe adverse events and fatalities.

Alghafees et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

October 9, 2025Open Access

View Full Paper

Ask AI

Bookmark

Authors

This systematic review evaluates immunotherapy outcomes in bladder cancer, suggesting intravesical strategies outperform systemic therapies.

Intravesical therapies exhibited superior efficacy in bladder cancer treatment, highlighting their promise in clinical management.
Nadofaragene Firadenovec achieved a remarkable complete response rate of 75.2% with durability exceeding 12 months.
Phase 2 and 3 clinical trials were used to synthesize findings, demonstrating a preference for intravesical immunotherapy approaches.
Intravesical strategies exhibit better safety profiles compared to systemic treatments, reducing severe adverse events and fatalities.

Alghafees et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark